ライフサイエンスコーパス: lysophospholipid

1 are phospholipids with one fatty acid tail (lysophospholipids).

2 free fatty acid, e.g., arachidonate, and a 2-lysophospholipid.

3 at were modified by the incorporation of the lysophospholipid.

4 -or-none by simply adding a defect-promoting lysophospholipid.

5 acid (LPA), a pleiotropic growth-factor-like lysophospholipid.

6 lglyerol, thus forming triacylglycerol and a lysophospholipid.

7 osition generating polyunsaturated sn-2-acyl lysophospholipids.

8 opology through the generation of asymmetric lysophospholipids.

9 y adding a palmitate to the sn-2 position of lysophospholipids.

10 ane phospholipids to release fatty acids and lysophospholipids.

11 and structure by altering phospholipids and lysophospholipids.

12 fied through the asymmetric incorporation of lysophospholipids.

13 ), a precursor of prostaglandins, as well as lysophospholipids.

14 protected isoprostanes to the corresponding lysophospholipids.

15 2 and DeltaC2 both had activity on monomeric lysophospholipids.

16 ed an increase in phosphatidic acid (PA) and lysophospholipids.

17 es of neutrophils to release fatty acids and lysophospholipids.

18 ty acids including arachidonic acid (AA) and lysophospholipids.

19 drug did not appear to block reacylation of lysophospholipids.

20 s, leading to the release of fatty acids and lysophospholipids.

21 deficient cells and tissues accumulate toxic lysophospholipids.

22 ic acids leads to a range of self-assembling lysophospholipids.

23 resulting in the release of fatty acids and lysophospholipids.

24 de a reduction in specific phospholipids and lysophospholipids.

25 they prefer lysophosphatidic acid over other lysophospholipids.

26 ys a surface groove to bind a limited set of lysophospholipids.

27 o acids, nucleobase-containing compounds and lysophospholipids.

28 transfers fatty acids from phospholipids to lysophospholipids.

29 ht subjects had different profiles of plasma lysophospholipids.

30 l membranes, liberating free fatty acids and lysophospholipids.

31 incorporation with a significant decrease in lysophospholipids.

32 ipids to yield nonesterified fatty acids and lysophospholipids.

33 st SocA dehydrogenase activity contained the lysophospholipid 1-acyl 2-hydroxy-sn-glycerophosphoethan

34 ects resulting from the incorporation of the lysophospholipid 1-myristoyl-2-hydroxy-sn-glycerol-3-pho

35 that large amounts of the phospholipids are lysophospholipids (30-45%), which mutant studies reveal

36 These results demonstrated that reduction of lysophospholipid absorption enhances insulin-mediated gl

37 he intestinal lumen facilitates postprandial lysophospholipid absorption, which suppresses hepatic fa

38 elet activating factor (PAF) to a variety of lysophospholipid acceptors.

39 ing site to facilitate efficient flipping of lysophospholipid across the cell membrane.

40 two enzymes to cooperate efficiently to move lysophospholipids across the bacterial membrane and cata

41 t the mechanisms involve both attenuation of lysophospholipid actions at cell surface receptors and o

42 n blotting analyses revealed that 12(S)-HETE-lysophospholipids activated the phosphorylation of NFkap

43 Lysophospholipid activity was dependent on lipid structu

44 sal was found to directly inhibit neutrophil lysophospholipid:acyl-CoA acyltransferase activity at th

45 yl-LPEAT activities but did not affect other lysophospholipid acylating activities.

46 evels of secretory phospholipase A2 (sPLA2), lysophospholipid acyltransferase (LPEAT), lysophosphatid

47 Our findings suggest that lysophospholipid acyltransferase activity is essential f

48 LPCAT1 and LPCAT2 encode the major lysophospholipid acyltransferase activity of the chlorop

49 (PG) E2, and PGD2 production, in addition to lysophospholipid acyltransferase activity.

50 (LPC), and LPC can be converted to PC by the lysophospholipid acyltransferase Ale1.

51 ents the identification of a plasma membrane lysophospholipid acyltransferase and establishes the fun

52 cumulation of lysophospholipids induced by a lysophospholipid acyltransferase inhibitor extensively v

53 gene encoding a mammalian acyl-CoA-dependent lysophospholipid acyltransferase with prominent activity

54 The major yeast lysophospholipid acyltransferase, Ale1p, is related to m

55 s shown that this enzyme can also serve as a lysophospholipid acyltransferase.

56 members of a superfamily of enzymes known as lysophospholipid acyltransferases (LPLATs), which are pr

57 Acyl-CoA-dependent lysophospholipid acyltransferases play an important role

58 much less affected, demonstrating that other lysophospholipid acyltransferases than the two LPEATs co

59 (Oys), Nessy (Nes), and Farjavit (Frj), are lysophospholipid acyltransferases.

60 transferred to lysophospholipids by acyl-CoA:lysophospholipid acyltransferases.

61 c activity but retain their side activity as lysophospholipid acyltransferases.

62 Solubilization with lysophospholipids again resulted in drastic losses of en

63 yl ether phosphodiesters of GS-441524 (RVn), lysophospholipid analogs which allow for oral bioavailab

64 icient route to enantiomerically homogeneous lysophospholipid analogues from D-mannitol 1,2:5,6-bis-a

65 as dependent on the glycerol backbone of the lysophospholipid and increased with acyl chain length, w

66 er, the mechanisms by which Spns1 transports lysophospholipid and proton sensing remain unclear.

67 potent signaling properties of 2-12(S)-HETE-lysophospholipids and 12(S)-HETE by their ability to rel

68 ion of ion pairing and self-assembly between lysophospholipids and acyl donors.

69 tivate a carboxylesterase known to hydrolyze lysophospholipids and acylated proteins in eukaryotes.

70 ellular membranes to catalyze the release of lysophospholipids and arachidonic acid.

71 study of fibrotic mediators have centered on lysophospholipids and eicosanoids.

72 Obesity was inversely associated lysophospholipids and ether linked phosphatidylcholines.

73 ndent on phospholipase A2 (PLA2) to mobilize lysophospholipids and free fatty acids to sustain fatty

74 ) hydrolyze glycerophospholipids to liberate lysophospholipids and free fatty acids.

75 bstrates releasing free arachidonic acid and lysophospholipids and giving rise to the generation of d

76 LplT catalyzes the transbilayer movement of lysophospholipids and is the first example of a phosphol

77 /RAS mutant cells exhibit enhanced uptake of lysophospholipids and lipid storage, coupled to augmente

78 Free fatty acids, eicosanoids, lysophospholipids and PAF are potent regulators of infla

79 The relative potencies of lysophospholipids and PUFAs are such that lysophosphatid

80 +)-ATPases evolved as specific receptors for lysophospholipids and support the hypothesis that lysoph

81 with child's age, whereas the corresponding lysophospholipids and triglycerides decreased.

82 ed with the hydrolysis of phospholipids into lysophospholipids and unesterified fatty acids.

83 -position to yield a free fatty acid and a 2-lysophospholipid, and iPLA(2)beta has been reported to p

84 ll as cyprinol sulfate and taurocholic acid, lysophospholipids, and a decrease in sphingosine levels

85 cluding flavonoids, fatty acids, terpenoids, lysophospholipids, and a galactolipid could be pointed o

86 n concentration influenced the percentage of lysophospholipids, and cyclo-propane bonds containing ac

87 ta) causes accumulation of arachidonic acid, lysophospholipids, and eicosanoids that can promote infl

88 ids (glycerides, fatty acids, phospholipids, lysophospholipids, and galactolipids) and implemented a

89 f LPT1 abrogated the esterification of other lysophospholipids, and overexpression increased lysophos

90 ospholipid hydrolysis, production of choline lysophospholipids, and PAF synthesis.

91 eramide, sphingomyelin, phosphatidylcholine, lysophospholipids, and phosphatidylethanolamine was obse

92 ic oxidation of the resultant 2-arachidonoyl-lysophospholipids, and the esterification of oxidized 2-

93 that, in addition to self-glycolipids, self-lysophospholipids are also recognized by type II NKT cel

94 ors for the serine protease thrombin and for lysophospholipids are coupled to G proteins and control

95 hospholipids and support the hypothesis that lysophospholipids are important plant signaling molecule

96 Because lysophospholipids are involved during inflammation, our

97 s including calmodulin, protein kinase C and lysophospholipids are involved in SOC activation.

98 These findings provide insight into how lysophospholipids are presented by human CD1d molecules

99 Lysophospholipids are self-antigens presented by CD1d th

100 ngle chromatographic step, phospholipids and lysophospholipids are separated and recovered for quanti

101 Phospholipids, predominantly lysophospholipids, are present in tears.

102 Here, we discover lysophospholipids as endogenous pannexin activators, usi

103 r glycerol-3-phosphate or a variety of other lysophospholipids as substrates, including lysophosphati

104 Proinflammatory immune mediators, lysophospholipids as well as cytokines such as CXCL10 an

105 Herein, we demonstrate that 2-12(S)-HETE-lysophospholipids as well as nonesterified 12(S)-HETE ar

106 ansferase activity toward a variety of other lysophospholipids, as well as neutral lipid substrates,

107 pholipids using a combination of an in vitro lysophospholipid binding assay using purified protein an

108 IFN, however, later represses NLRC4 and the lysophospholipid biosynthetic enzyme iPLA2, causing a de

109 , low nanomolar concentrations of 12(S)-HETE-lysophospholipids, but not other oxidized signaling lipi

110 volves the generation of membrane-associated lysophospholipids by a cytoplasmic Ca2+-independent phos

111 m in which in situ generation of nonlamellar lysophospholipids by ACT-PLA activity into the cell memb

112 he esterification of oxidized 2-arachidonoyl-lysophospholipids by acyl-CoA-dependent sn-1 acyltransfe

113 A by acyl-CoA synthetases and transferred to lysophospholipids by acyl-CoA:lysophospholipid acyltrans

114 s in early- (diacylglycerols) or late-stage (lysophospholipids) cases, and multiple lipids in plasma

115 utagenesis to delineate the active domain of lysophospholipid catalytic activity and to examine poten

116 The various lysophospholipids caused the efflux of cellular choleste

117 LC separation of individual phospholipid and lysophospholipid classes.

118 overed by enzymatic degumming contained more lysophospholipids compared to water degumming.

119 Two lysophospholipids comprising approximately 10% of all ph

120 results suggest that LysoPC, an atherogenic lysophospholipid contained in oxidized LDL, rapidly indu

121 phosphatidylcholine (LysoPC), an atherogenic lysophospholipid contained in oxidized low-density lipop

122 36(-/-) myocardium associated with increased lysophospholipid content and a higher proportion of 22:6

123 The elevation in free fatty acids and lysophospholipids correlated with increased expression o

124 A multivariate combination of the 26 lysophospholipids could discriminate between normal-weig

125 ibited by perifosine, an orally active alkyl-lysophospholipid currently being evaluated as an anti-ca

126 A number of lysophospholipids demonstrated increased ion signal in a

127 gnificantly higher amounts of phospholipids, lysophospholipids, diacylglycerols, sterols, and sulfoli

128 optosis, suggesting that the accumulation of lysophospholipids did not account for the decrease in Co

129 Activation of the plant pump by lysophospholipids did not involve the penultimate residu

130 s with cultured hepatoma cells revealed that lysophospholipids dose-dependently suppressed insulin-st

131 d residues, e.g. linoleate (C18:2), to yield lysophospholipids, e.g. monolysocardiolipin (MLCL), that

132 but do confer cross sensitivity to the alkyl-lysophospholipid edelfosine, which is known to displace

133 sPLA2-IIA yields inflammatory mediators (ie, lysophospholipids, fatty acids, and mtDNA) that promote

134 Lysophosphatidic acid (LPA) is a major lysophospholipid found systemically, and its levels are

135 Isolated phospholipid and lysophospholipid fractions are available for separation

136 In contrast, the outer layer contained more lysophospholipids, free fatty acids, and lipid degradati

137 AdPLA generated free fatty acid and lysophospholipid from phosphatidylcholine with a prefere

138 Recovery of phospholipids and lysophospholipids from HPLC averages 80-90%.

139 e now report that lipid fractions containing lysophospholipids from oxidized LDL or phospholipase A2-

140 ds, including arachidonic acid, and generate lysophospholipids from phospholipids, including membrane

141 ll neoantigens, such as free fatty acids and lysophospholipids, from common phosphodiacylglycerides.

142 Sphingosine-1-phosphate (S1P) is a bioactive lysophospholipid generated by the sphingosine kinase (SK

143 Analyses of the lysophospholipids generated during activation reveal tha

144 In these cells, S1P, a biologically active lysophospholipid, greatly enhances increases in intracel

145 Sphingosine 1-phosphate (S1P), a lysophospholipid, has gained relevance to multiple scler

146 In this study, lysophospholipids have been identified by mass spectrome

147 the metabolic pathways generating eicosanoid-lysophospholipids have been increasingly appreciated, th

148 Lysophospholipids have emerged as biologically important

149 Plasma lysophospholipids have emerged as signaling molecules wi

150 ion of CD1d contains bound sphingomyelin and lysophospholipids in addition to phosphatidyl choline.

151 However, parental CHO-K1 cells respond to lysophospholipids in in-vitro functional assays, which s

152 ng a previously unknown role of 2-12(S)-HETE-lysophospholipids in mediating inflammatory responses.

153 on can result from increasing the content of lysophospholipids in membranes, either by stimulation of

154 roduction of 2-AA-LPC, 2-AA-LPE, and 12-HETE-lysophospholipids in mouse platelets.

155 Next, we identified these two eicosanoid-lysophospholipids in murine myocardium and in isolated p

156 amount of dietary phospholipids absorbed as lysophospholipids in Pla2g1b-/- mice compared with that

157 against glycerol 3-phosphate or a variety of lysophospholipids, including lysophosphatidylcholine, ly

158 PLA2 enzymes release fatty acids and lysophospholipids, including the precursor of platelet-a

159 tantially in sequence bind the same array of lysophospholipids indicates that the amino acid polymorp

160 blood mononuclear cells with an inflammatory lysophospholipid induced beta-galactosidase and sialidas

161 Moreover, accumulation of lysophospholipids induced by a lysophospholipid acyltran

162 d that neither SPC nor LPC, or other related lysophospholipids, induced internalization of GPR4 from

163 The lysophospholipid-inducible beta-galactosidase activity o

164 ing membrane spontaneous curvature by adding lysophospholipids inhibits the lipid mixing observed for

165 hosphate (SPP), a platelet-derived bioactive lysophospholipid, is a regulator of angiogenesis.

166 When both lysophospholipid isomers are present in a 1:1 mixture un

167 Elevating plasma lysophospholipid levels in Pla2g1b-/- mice via intraperi

168 reoperative plasma samples were analyzed for lysophospholipid levels using liquid chromatography mass

169 h coincided with reduced postprandial plasma lysophospholipid levels.

170 A hydrophobic zwitterionic lysophospholipid ligand with difficult physical properti

171 AR of LPA(5) using LPA analogs and other non-lysophospholipid ligands.

172 that might also encode receptors for related lysophospholipid ligands.

173 bioactive lipid species that is part of the lysophospholipid (LP) family.

174 ne phospholipids are metabolized into potent lysophospholipid (LP) mediators, such as sphingosine 1-p

175 reated macrophages suggest that ethanolamine lysophospholipid (LPE) is an sPLA2-V-derived product tha

176 e characterised by a pronounced depletion of lysophospholipids (LPE, LPC, LPG, LPI; fold change < 0.5

177 The lysophospholipid (LPL) mediators lysophosphatidic acid (

178 A platform for comprehensive analysis of lysophospholipid (LPL) species based on shotgun lipidomi

179 Lysophospholipids (LPLs) (lysophosphatidylcholine, lysop

180 phatidylcholine (palmitoyl lyso-PC) or other lysophospholipids (lyso-PLs) and palmitoyl ceramide (PCe

181 ervations prompted the hypothesis that other lysophospholipids (lyso-PLs) may also signal for human n

182 ith obesity (OB) revealed several species of lysophospholipids (lyso-PLs) that were differentially ab

183 Lysophospholipids (lyso-PLs), including various glycerol

184 Phospholipid vesicles and lysophospholipid (lysolipid) micelles were employed as m

185 Thrombin and the lysophospholipids lysophosphatidic acid and sphingosine

186 The proinflammatory lysophospholipid, lysophosphatidic acid (LPA), which is

187 taxis; whereas, another structurally related lysophospholipid, lysophosphatidic acid, did not compete

188 The lysophospholipids, lysophosphatidic acid (LPA) and sphin

189 The lysophospholipids, lysophosphatidic acid, sphingosine-1-

190 which liberates large amounts of AA and the lysophospholipid lysophosphatidylcholine (LPC), from mem

191 ME (epoxide of linoleic acid) as well as the lysophospholipids lysophosphatidylcholine (LPC) 18:1 and

192 treatment, which revealed a crucial role of lysophospholipids lysophosphatidylcholine (LPC) 18:1, LP

193 plicated G2A as a receptor for the bioactive lysophospholipid, lysophosphatidylcholine (LPC).

194 gests a role for GPR55 as a receptor for the lysophospholipid lysophosphatidylinositol (LPI).

195 n of TLR4 agonists, which were identified as lysophospholipids (lysoPLs) with oxidized unsaturated ac

196 Further, lysophospholipids may be cytotoxic and/or impair the fun

197 The unique mode of signaling of this lysophospholipid mediator is providing novel opportuniti

198 This has revealed fundamental principles of lysophospholipid mediator signaling that not only clarif

199 Lysophosphatidic acid (LPA) is a bioactive lysophospholipid mediator that acts through G protein-co

200 Sphingosine 1-phosphate (S1P) is a lysophospholipid mediator that evokes a variety of cell

201 (LPA) and sphingosine-1-phosphate (S1P) are lysophospholipid mediators of diverse cellular processes

202 l challenge to better understand the role of lysophospholipid metabolism in the progression of obesit

203 ting that obesity impairs the sensitivity of lysophospholipid metabolism to n-3 PUFAs.

204 Obesity has a substantial impact on lysophospholipid metabolism, altering the plasma lysopho

205 n, multiple members of the sphingomyelin and lysophospholipid metabolite classes had significantly po

206 Zwitterionic lysophospholipid micelles are able to induce the beta-sh

207 ter for construction of the optically active lysophospholipid molecule, (2) tetrahydropyranylation of

208 Stimulation by lysophospholipids occurs through G(i), whereas thrombin

209 Our findings extend the influence of lysophospholipids on immune function and suggest that al

210 from the accumulation of anionic lipids and lysophospholipids on the particle surface and/or from pr

211 A2 products (polyunsaturated fatty acids and lysophospholipids) on the cold-sensitive channel transie

212 and EDG-4 suggested that its ligand may be a lysophospholipid or lysosphingolipid.

213 pids as well as other family lipids, such as lysophospholipids or sphingomyelin, were found significa

214 ; upregulated metabolites were enriched with lysophospholipids (P = 3.4e-4).

215 transacylations between various phospholipid-lysophospholipid pairs, it showed the highest rate for t

216 epG2 cells affected the secretion pattern of lysophospholipids, partially resembling the changes obse

217 eacetylase inhibitors (HDACIs) and the alkyl-lysophospholipid perifosine were examined in human leuke

218 various glycerol-based and sphingosine-based lysophospholipids, play important roles in many biochemi

219 Sphingosine 1-phosphate (S1P), a lysophospholipid, plays an important chemotactic role in

220 alpha-chloro fatty aldehydes and unsaturated lysophospholipids, possess proatherogenic properties, as

221 sed in yeast, these MBOATs esterify specific lysophospholipids preferentially with unsaturated fatty

222 n, and characterization of phospholipids and lysophospholipids present in complex biological samples.

223 PLA I may play an important role in removing lysophospholipids produced by both phospholipase A1 and

224 Lysophospholipids produced by Pla2g1b hydrolysis suppres

225 genase-catalyzed oxidation of 2-arachidonoyl-lysophospholipids produced from either phospholipase A(1

226 at cell surface receptors and opposition of lysophospholipid production.

227 Both AA and lysophospholipid, products of the enzymic reaction, can

228 phospholipid metabolism, altering the plasma lysophospholipid profile and abolishing its sensitivity

229 ds with positive intrinsic curvature such as lysophospholipids promoted membrane permeabilization, wh

230 Polyunsaturated fatty acids and lysophospholipids protect the brain against global ischa

231 for this idea by showing that inhibition of lysophospholipid reacylation by a novel Golgi-associated

232 g the G protein-coupled receptor LPA1/VZG-1 (lysophospholipid receptor A1/ventricular zone gene-1), r

233 nding the biological roles of this enlarging lysophospholipid receptor family.

234 derlying lysophosphatidic acid signaling and lysophospholipid receptor gene evolution, these results

235 affinity ligand, belongs to a newly defined lysophospholipid receptor subfamily.

236 ese results confirm LPA(5) to be a bona fide lysophospholipid receptor.

237 d receptors, encoded by genes designated lp (lysophospholipid) receptor or edg (endothelial different

238 S1P4, and S1P5), collectively referred to as lysophospholipid receptors (lpR).

239 in polymerization (even after stimulation of lysophospholipid receptors).

240 his brief review, we note cogent features of lysophospholipid receptors, including the current nomenc

241 protein-coupled, alpha/beta-adrenergic, and lysophospholipid receptors.

242 ysLT synthesis and arachidonic acid (AA) and lysophospholipid release by eosinophils mediated by reco

243 dicate that sPLA(2)-X participates in AA and lysophospholipid release, resulting in CysLT synthesis i

244 that lysophosphatidylcholine (LPC), the main lysophospholipid released in response to sPLA2-X activit

245 iated, the signaling functions of eicosanoid-lysophospholipids remain largely unknown.

246 Compared with other known factors, lysophospholipids represent the major activator of calci

247 essential for embryogenesis by supplying the lysophospholipid S1P, which regulates embryonic vascular

248 zone depends on responsiveness to the blood lysophospholipid S1P, with S1P(1) signaling overcoming t

249 e implicating LPPs as negative regulators of lysophospholipid signaling and suggest that the mechanis

250 f neurons and oligodendrocytes and implicate lysophospholipid signaling as a potential regulator of m

251 mplicate G protein-coupled receptor-mediated lysophospholipid signaling as a significant mechanism in

252 Our results provide evidence that endogenous lysophospholipid signaling requires an lp receptor gene

253 , we have identified an intricate network of lysophospholipid signalling by splenic macrophages that

254 Importantly, the following lysophospholipid species are significantly increased in

255 Exogenous sPLA(2)-X released lysophospholipid species that arise from phospholipids e

256 or an acyltransferase that uses a variety of lysophospholipid species, including 1-acyl-sn-glycerol-3

257 Here we show that lysophospholipids specifically activate a plant plasma m

258 lacking Ale1p and studied their acyl-CoA and lysophospholipid specificities using novel mass spectrom

259 OSE OF REVIEW: Lipid mediators including the lysophospholipids, sphingolipids and eicosanoids have lo

260 The lysophospholipid sphingosine 1-phosphate (S1P) is a plei

261 The lysophospholipid sphingosine 1-phosphate (S1P) promotes

262 hat lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a

263 S1PR1), a G protein-coupled receptor for the lysophospholipid sphingosine-1-phosphate (S1P), is eleva

264 In this study, fingolimod (FTY720), a lysophospholipid sphingosine-1-phosphate receptor modula

265 A new study shows that HDL-associated lysophospholipids stimulate the production of the potent

266 This effect was specific in terms of lysophospholipid structure.

267 to form a hydrophobic channel through which lysophospholipid substrates enter and leave the active s

268 The signaling effects of lysophospholipids such as lysophosphatidic acid (LPA) ar

269 hesis that Pla2g1b and its lipolytic product lysophospholipid suppress hepatic fat utilization and en

270 hosphatidic acid (LPA) is a membrane-derived lysophospholipid that can induce pleomorphic effects in

271 Sphingosine-1-phosphate (S1P) is a lysophospholipid that evokes a variety of biological res

272 Sphingosine 1-phosphate (S1P) is a lysophospholipid that exerts a variety of responses in c

273 Lysophosphatidic acid (LPA) is a bioactive lysophospholipid that signals through G protein-coupled

274 ciated endogenous antigenic lipids including lysophospholipids that are generated by HBV-induced secr

275 sis of phospholipids to inverted-cone-shaped lysophospholipids that contribute to membrane curvature

276 The many biological responses documented for lysophospholipids that include lysophosphatidic acid and

277 generates previously unrecognized eicosanoid-lysophospholipids that may serve as biomarkers for age-r

278 me iPLA2, causing a decline in intracellular lysophospholipids that results in down-regulation of fla

279 reover, SAA sequestered free fatty acids and lysophospholipids to form stable proteolysis-resistant c

280 s study was to assess the response of plasma lysophospholipids to obesity, n-3 PUFA consumption, and

281 These were termed as PAF:lysoplasmalogen (lysophospholipid) transacetylase and PAF:sphingosine tra

282 The tafazzin gene encodes a phospholipid-lysophospholipid transacylase involved in cardiolipin me

283 acids between phospholipids by phospholipid-lysophospholipid transacylation.

284 Lysophospholipid transporter (LplT) was previously found

285 This work identifies and characterizes a lysophospholipid transporter gene (lplT, formally ygeD)

286 EfpA resembles the related lysophospholipid transporter MFSD2A in both overall stru

287 However, lysophospholipid treatment of peripheral blood mononucle

288 ependent manner but hydrolyzes ceramides and lysophospholipids via bile salt-independent mechanisms.

289 over, TNFalpha release induced by 12(S)-HETE-lysophospholipids was inhibited by the TNFalpha converti

290 on following exposure to LPA but not related lysophospholipids was observed.

291 The profile of secreted lysophospholipids was studied in HepG2 cells under palmi

292 Plasma levels of lysophospholipids were evaluated as potential biomarkers

293 Recently, eicosanoid-lysophospholipids were identified as novel metabolites g

294 tiates pyroptosis and concomitant release of lysophospholipids which in turn enhance expression of fl

295 nent activity toward ethanolamine-containing lysophospholipids, which we termed acyl-CoA:lysophosphat

296 The abundant lysophospholipid with the mass m/z 450 (molecular ion [M

297 esteryl esters (CE), triglycerides (TG), and lysophospholipids, with CE and TG hydrolysis stimulated

298 To show that lysophospholipids within an intact lipoprotein were acti

299 studies showed that injected PLA2 generates lysophospholipids within human skin in vivo, and polyclo

300 e expansion by fine-tuning the generation of lysophospholipids within the vacuolar membrane.